scholarly journals Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up.

1989 ◽  
Vol 48 (8) ◽  
pp. 667-671 ◽  
Author(s):  
V Kyle ◽  
T E Cawston ◽  
B L Hazleman
Keyword(s):  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Erythrocyte Sedimentation Rate ◽  
Sedimentation Rate ◽  
Polymyalgia Rheumatica ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Erythrocyte Sedimentation

Microheterogeneity of α1-antichymotrypsin in the management of giant-cell arteritis and polymyalgia rheumatica

1990 ◽  
Vol 78 (6) ◽  
pp. 557-564 ◽  
Author(s):  
Eric Hachulla ◽  
Anne Laine ◽  
Annette Hayem
Keyword(s):  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Erythrocyte Sedimentation Rate ◽  
Concanavalin A ◽  
Sedimentation Rate ◽  
Polymyalgia Rheumatica ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Erythrocyte Sedimentation ◽  
Active Disease

1. Using crossed immunoaffinity electrophoresis with free concanavalin A in the first dimension, we studied the glycan microheterogeneity of α1-antichymotrypsin in sera from patients with giant-cell arteritis and/or polymyalgia rheumatica, and its variation in the serum of several of these patients during induction of disease remission by prednisone therapy and possible further recurrence of giant-cell arteritis and/or polymyalgia rheumatica. 2. In the serum of patients with active disease we observed increased proportions of concanavalin A non-reactive and concanavalin A weakly reactive fractions. The results were expressed as the ratio of concanavalin A non-reactive fraction plus concanavalin A weakly reactive fraction to concanavalin A reactive fraction, called Rα1-ACT. An Rα1-ACT higher than 1.8 (upper normal value) was found in 30/31 sera from patients with active disease (sensitivity 97%) and in 2/22 sera from patients with inactive disease (specificity 91%). 3. The erythrocyte sedimentation rate and the serum C-reactive protein level, common markers of biological inflammation, are usually elevated in active giant-cell arteritis and/or polymyalgia rheumatica. The two parameters are commonly used to guide the therapy during the course of the disease, but they have no specificity. An erythrocyte sedimentation rate of greater than 30 mm/h was found in 30/31 sera from patients with active disease (sensitivity 97%) and in 5/22 sera from patients with inactive disease (specificity 77%). Our results show that α1-antichymotrypsin microheterogeneity provides a precise marker of giant-cell arteritis and/or polymyalgia rheumatica activity, particularly when the serum C-reactive protein level is normal or when the erythrocyte sedimentation rate is still high in treated patients. We found a better positive prediction value for Rα1-ACT than for erythrocyte sedimentation rate (94% and 86%, respectively). By determining the Rα1-ACT it is thus possible to follow the exacerbation of the disease when the dose of prednisone is tapered. 4. The correlation coefficients between clinical symptoms, erythrocyte sedimentation rate, levels of C-reactive protein or α1-antichymotrypsin, and Rα1-ACT values were determined. The highest correlation occurred between Rα1-ACT and erythrocyte sedimentation rate (r = 0.57, P <0.0001). 5. Three case reports illustrated the value of determining Rα1-ACT as a useful adjunct test for the diagnosis of giant-cell arteritis and/or polymyalgia rheumatica.

scholarly journals Utility of Erythrocyte Sedimentation Rate and C-Reactive Protein for the Diagnosis of Giant Cell Arteritis

2012 ◽  
Vol 41 (6) ◽  
pp. 866-871 ◽  
Author(s):  
Tanaz A. Kermani ◽  
Jean Schmidt ◽  
Cynthia S. Crowson ◽  
Steven R. Ytterberg ◽  
Gene G. Hunder ◽  
...  
Keyword(s):  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Erythrocyte Sedimentation Rate ◽  
Sedimentation Rate ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Erythrocyte Sedimentation
Sign in / Sign up

Export Citation Format

Share Document